BEIGENE(06160),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

06160 BEIGENE

Closed 05-17 16:08:17

103.600

+1.700

+1.67%

High104.800	Low102.000	Vol1.64M
Open102.600	D1 Closing101.900	Amplitude2.75%
Mkt Cap140.85B	Tradable Cap140.85B	Total Shares1.36B
T/O170.07M	T/O Rate0.12%	Tradable Shares1.36B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"BEIGENE","latestPrice":103.6,"timestamp":1715933297036,"preClose":101.9,"halted":0,"volume":1644797,"delay":0,"floatShares":1359524369,"shares":1359524369,"eps":-5.069448995833528,"marketStatus":"Closed","change":1.7,"latestTime":"05-17 16:08:17","open":102.6,"high":104.8,"low":102,"amount":170068034,"amplitude":0.027478,"askPrice":103.6,"askSize":116400,"bidPrice":103.1,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-4.508980540861071,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1716168600000},"marketStatusCode":5,"adr":0,"listingDate":1533657600000,"exchange":"SEHK","adjPreClose":101.9,"openAndCloseTimeList":[[1715909400000,1715918400000],[1715922000000,1715932800000]],"volumeRatio":1.028928,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"Beigene, Ltd.","latestPrice":133.37,"timestamp":1715929200000,"preClose":131.63,"halted":0,"volume":1112300,"delay":0,"premium":"-27.98"}},"requestUrl":"/m/hq/s/06160","defaultTab":"news","newsList":[{"id":"2434363400","title":"BUZZ-BeiGene's Hong Kong stock jumps most in 6 months on smaller Q1 loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2434363400","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2434363400?lang=en_us&edition=fundamental","pubTime":"2024-05-09 11:07","pubTimestamp":1715224056,"startTime":"0","endTime":"0","summary":"** Hong Kong shares of Chinese oncology medicines developer BeiGene Ltd    jump 7.5% to HK$101.90, on course for the biggest one-day pct rise since Nov 6 if gains hold   ** Stock hits the highest since March 21, on track to snap two straight sessions of decline   ** Shanghai-listed stock    rises 5.2% to 141.30 yuan, highest since March 21   ** BeiGene says its Q1 net loss 1.91 bln yuan , compared with 2.45 bln yuan loss in the year-earlier period, with revenue up 74.8% YoT to 5.36 bln yuan   ** The Hang Seng Commerce & Industry Index    rises 1.1%, healthcare    surges 2.9% and the Hang Seng Index  gains 0.6%   ** Co's Hong Kong-listed shares down 7.7% YTD, while Shanghai stock up 1.4% YTD ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433749837","title":"BRIEF-Beigene's Q1 Net Loss 1.9 Bln Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2433749837","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2433749837?lang=en_us&edition=fundamental","pubTime":"2024-05-08 18:41","pubTimestamp":1715164865,"startTime":"0","endTime":"0","summary":"May 8 (Reuters) - Beigene   :   * SAYS Q1 NET LOSS AT 1.9 BILLION YUAN  ($262.96 million)    Source text  Further company coverage:   ($1 = 7.2254 Chinese yuan renminbi) (Reporting by Beijing newsroom)((Ella.Cao@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433437447","title":"BeiGene Q1 2024 GAAP EPADS $(2.41) Beats $(2.89) Estimate, Sales $751.652M Beat $676.451M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2433437447","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2433437447?lang=en_us&edition=fundamental","pubTime":"2024-05-08 18:10","pubTimestamp":1715163027,"startTime":"0","endTime":"0","summary":"BeiGene (NASDAQ:BGNE) reported quarterly losses of $(2.41) per share which beat the analyst consensus estimate of $(2.89) by 16.61 percent. This is a 27.84 percent increase over losses of $(3.34) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38694178/beigene-q1-2024-gaap-epads-2-41-beats-2-89-estimate-sales-751-652m-beat-676-451m-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2432326406","title":"BeiGene, AbbVie patent spat to get trial from USPTO appeals board","url":"https://stock-news.laohu8.com/highlight/detail?id=2432326406","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432326406?lang=en_us&edition=fundamental","pubTime":"2024-05-02 04:12","pubTimestamp":1714594341,"startTime":"0","endTime":"0","summary":"The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office has decided to institute a trial in a patent dispute involving BeiGene  and AbbVie  unit Pharmacyclics. Pharmacyclics has accused BeiGene's Brukinsa  of violating a patent belonging to Imbruvica . Both are BTK inhibitors approved to treat different types of leukemia and lymphoma.  AbbVie , which markets Imbruvica with Johnson & Johnson's  Janssen unit, brought a patent suit against BeiGene  in June 2023 in a Delaware federal court. That lawsuit was filed the same day a key Imbruvica patent was issued. BeiGene filed its appeal request as petitioner with PTAB on Nov. 1, 2023. Pharmacyclics is listed as the respondent. The patent in question, No. 11,672,803, involves the method of use for a BTK inhibitor created under a particular chemical structure for treating chronic lymphocytic leukemia or small lymphocytic lymphoma.","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/899094824/image_899094824.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/899094824/image_899094824.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4097839-beigene-abbvie-patent-spat-get-trial-uspto-appeals-board","is_publish_highlight":false,"gpt_icon":0},{"id":"2429116810","title":"BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2429116810","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2429116810?lang=en_us&edition=fundamental","pubTime":"2024-04-23 22:43","pubTimestamp":1713883380,"startTime":"0","endTime":"0","summary":"BeiGene shares were up 7% to $139.39 after the company said the European Commission has approved tislelizumab as a treatment for non-small cell lung cancer across multiple tumor types.The approved indications for tislelizumab are, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of adult patients with squamous non-small cell lung cancer. It also can be used as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer after prior platinum-based therapy.BeiGene plans to combine the non-small cell lung cancer indications with the second-line indication under the brand name Tevimbra, which will launch in the first EU countries later in 2024. Tevimbra is approved in the U.S. and EU after prior chemotherapy.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2429934262","title":"Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?","url":"https://stock-news.laohu8.com/highlight/detail?id=2429934262","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2429934262?lang=en_us&edition=fundamental","pubTime":"2024-04-21 22:53","pubTimestamp":1713711232,"startTime":"0","endTime":"0","summary":"Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bgne/beigene/news/is-beigene-nasdaqbgne-using-too-much-debt","is_publish_highlight":false,"gpt_icon":0},{"id":"2425958426","title":"China's Hillhouse logs hefty decline in hedge fund assets in 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2425958426","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2425958426?lang=en_us&edition=fundamental","pubTime":"2024-04-08 15:31","pubTimestamp":1712561516,"startTime":"0","endTime":"0","summary":"By Summer Zhen      HONG KONG, April 8 (Reuters) - Billionaire Zhang Lei's Hillhouse Investment saw its hedge fund assets plummet by a third last year to $27.5 billion, a U.S. regulatory filing showed","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2424271284","title":"BeiGene, Ltd. (NASDAQ:BGNE) is largely controlled by institutional shareholders who own 41% of the company","url":"https://stock-news.laohu8.com/highlight/detail?id=2424271284","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2424271284?lang=en_us&edition=fundamental","pubTime":"2024-03-31 22:52","pubTimestamp":1711896755,"startTime":"0","endTime":"0","summary":"Key Insights Given the large stake in the stock by institutions, BeiGene's stock price might be vulnerable to their...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bgne/beigene/news/beigene-ltd-nasdaqbgne-is-largely-controlled-by-institutiona","is_publish_highlight":false,"gpt_icon":0},{"id":"2423285914","title":"Clear Harbor Asset Management LLC Purchases Shares of 1155 BeiGene, Ltd. (NASDAQ:BGNE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2423285914","media":"Defense World","top":-1,"share":"https://ttm.financial/m/news/2423285914?lang=en_us&edition=fundamental","pubTime":"2024-03-30 19:03","pubTimestamp":1711796617,"startTime":"0","endTime":"0","summary":"Clear Harbor Asset Management LLC Purchases Shares of 1155 BeiGene, Ltd. (NASDAQ:BGNE)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"redbox_crawler","url":"https://news.google.com/rss/articles/CBMifmh0dHBzOi8vd3d3LmRlZmVuc2V3b3JsZC5uZXQvMjAyNC8wMy8zMC9jbGVhci1oYXJib3ItYXNzZXQtbWFuYWdlbWVudC1sbGMtcHVyY2hhc2VzLXNoYXJlcy1vZi0xMTU1LWJlaWdlbmUtbHRkLW5hc2RhcWJnbmUuaHRtbNIBAA?oc=5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.google.com/rss/articles/CBMifmh0dHBzOi8vd3d3LmRlZmVuc2V3b3JsZC5uZXQvMjAyNC8wMy8zMC9jbGVhci1oYXJib3ItYXNzZXQtbWFuYWdlbWVudC1sbGMtcHVyY2hhc2VzLXNoYXJlcy1vZi0xMTU1LWJlaWdlbmUtbHRkLW5hc2RhcWJnbmUuaHRtbNIBAA?oc=5","is_publish_highlight":false,"gpt_icon":0},{"id":"2422590680","title":"BeiGene, Ltd. (NASDAQ:BGNE) Shares Sold by LVW Advisors LLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2422590680","media":"Defense World","top":-1,"share":"https://ttm.financial/m/news/2422590680?lang=en_us&edition=fundamental","pubTime":"2024-03-25 19:05","pubTimestamp":1711364735,"startTime":"0","endTime":"0","summary":"BeiGene, Ltd. (NASDAQ:BGNE) Shares Sold by LVW Advisors LLC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"redbox_crawler","url":"https://news.google.com/rss/articles/CBMiY2h0dHBzOi8vd3d3LmRlZmVuc2V3b3JsZC5uZXQvMjAyNC8wMy8yNS9iZWlnZW5lLWx0ZC1uYXNkYXFiZ25lLXNoYXJlcy1zb2xkLWJ5LWx2dy1hZHZpc29ycy1sbGMuaHRtbNIBAA?oc=5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.google.com/rss/articles/CBMiY2h0dHBzOi8vd3d3LmRlZmVuc2V3b3JsZC5uZXQvMjAyNC8wMy8yNS9iZWlnZW5lLWx0ZC1uYXNkYXFiZ25lLXNoYXJlcy1zb2xkLWJ5LWx2dy1hZHZpc29ycy1sbGMuaHRtbNIBAA?oc=5","is_publish_highlight":false,"gpt_icon":0},{"id":"2421281573","title":"Citigroup Inc. Decreases Stock Position in BeiGene, Ltd. (NASDAQ:BGNE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2421281573","media":"Defense World","top":-1,"share":"https://ttm.financial/m/news/2421281573?lang=en_us&edition=fundamental","pubTime":"2024-03-24 17:03","pubTimestamp":1711271015,"startTime":"0","endTime":"0","summary":"Citigroup Inc. Decreases Stock Position in BeiGene, Ltd. (NASDAQ:BGNE)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"redbox_crawler","url":"https://news.google.com/rss/articles/CBMibWh0dHBzOi8vd3d3LmRlZmVuc2V3b3JsZC5uZXQvMjAyNC8wMy8yNC9jaXRpZ3JvdXAtaW5jLWRlY3JlYXNlcy1zdG9jay1wb3NpdGlvbi1pbi1iZWlnZW5lLWx0ZC1uYXNkYXFiZ25lLmh0bWzSAQA?oc=5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.google.com/rss/articles/CBMibWh0dHBzOi8vd3d3LmRlZmVuc2V3b3JsZC5uZXQvMjAyNC8wMy8yNC9jaXRpZ3JvdXAtaW5jLWRlY3JlYXNlcy1zdG9jay1wb3NpdGlvbi1pbi1iZWlnZW5lLWx0ZC1uYXNkYXFiZ25lLmh0bWzSAQA?oc=5","is_publish_highlight":false,"gpt_icon":0},{"id":"2420774043","title":"BeiGene Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2420774043","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2420774043?lang=en_us&edition=fundamental","pubTime":"2024-03-20 21:51","pubTimestamp":1710942660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BGNE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2024 09:51 ET (13:51 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2419027719","title":"BofA raises BeiGene stock target to $179.30 on strong drug sales growth By Investing.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2419027719","media":"Investing.com","top":-1,"share":"https://ttm.financial/m/news/2419027719?lang=en_us&edition=fundamental","pubTime":"2024-03-16 00:49","pubTimestamp":1710521373,"startTime":"0","endTime":"0","summary":"BofA raises BeiGene stock target to $179.30 on strong drug sales growth By Investing.com","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"redbox_crawler","url":"https://news.google.com/rss/articles/CBMigwFodHRwczovL3d3dy5pbnZlc3RpbmcuY29tL25ld3Mvc3RvY2stbWFya2V0LW5ld3MvYm9mYS1yYWlzZXMtYmVpZ2VuZS1zdG9jay10YXJnZXQtdG8tMTc5MzAtb24tc3Ryb25nLWRydWctc2FsZXMtZ3Jvd3RoLTkzQ0gtMzM0MDM5NdIBAA?oc=5","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.google.com/rss/articles/CBMigwFodHRwczovL3d3dy5pbnZlc3RpbmcuY29tL25ld3Mvc3RvY2stbWFya2V0LW5ld3MvYm9mYS1yYWlzZXMtYmVpZ2VuZS1zdG9jay10YXJnZXQtdG8tMTc5MzAtb24tc3Ryb25nLWRydWctc2FsZXMtZ3Jvd3RoLTkzQ0gtMzM0MDM5NdIBAA?oc=5","is_publish_highlight":false,"gpt_icon":0},{"id":"2419654229","title":"BRIEF-Beigene Receives FDA Approval For Tevimbra","url":"https://stock-news.laohu8.com/highlight/detail?id=2419654229","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2419654229?lang=en_us&edition=fundamental","pubTime":"2024-03-15 08:28","pubTimestamp":1710462526,"startTime":"0","endTime":"0","summary":"March 15  - Beigene Ltd   :   * BEIGENE RECEIVES FDA APPROVAL FOR TEVIMBRA   * FDA APPROVAL FOR TEVIMBRA  FOR TREATMENT OF ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER PRIOR CHEMOTHERAPYSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419955077","title":"BeiGene Says FDA Approves Tevimbra to Treat Some Esophageal Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2419955077","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2419955077?lang=en_us&edition=fundamental","pubTime":"2024-03-15 05:07","pubTimestamp":1710450420,"startTime":"0","endTime":"0","summary":"BeiGene on Thursday said the Food and Drug Administration approved Tevimbra to treat certain adult patients with unresectable or metastatic esophageal squamous cell carcinoma, or ESSC.The company said this was the first U.S. indication for Tevimbra, or tislelizumab-jsgr. The treatment will be available in the U.S. in the second half of this year, BeiGene said.The FDA is reviewing biologics license applications for tislelizumab \"as a first-line treatment for patients with unresectable, recurrent, locally advanced, or metastatic ESCC and patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma,\" BeiGene said.Tislelizumab has been approved for certain patients with advanced or metastatic ESCC after prior chemotherapy. It received a positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency earlier this year to treat non-small cell lung cancer across three indications, the oncology company sai","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2419934110","title":"BRIEF-U.S. FDA  Approves Beigene's Tevimbra As Of March 13, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2419934110","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2419934110?lang=en_us&edition=fundamental","pubTime":"2024-03-15 03:29","pubTimestamp":1710444548,"startTime":"0","endTime":"0","summary":"March 14 (Reuters) -    * U.S. FDA  APPROVES BEIGENE'S TEVIMBRA AS OF MARCH 13, 2024 - WEBSITE   * FDA: TEVIMBRA AS SINGLE AGENT IS FOR ADULTS WITH UNRESECTABLE/METASTATIC ESOPHAGEAL SQUAMOUS CELL CAR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419939730","title":"UPDATE 1-US FDA approves BeiGene's esophageal cancer therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2419939730","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2419939730?lang=en_us&edition=fundamental","pubTime":"2024-03-15 02:54","pubTimestamp":1710442442,"startTime":"0","endTime":"0","summary":"(Adds details in para 2,3 background throughout)      March 14 (Reuters) - The U.S. Food and Drug Administration said it has approved BeiGene's    drug to treat a type of advanced esophageal cancer in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419685570","title":"BeiGene Shares Rise on First Dosing of Brukinsa","url":"https://stock-news.laohu8.com/highlight/detail?id=2419685570","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2419685570?lang=en_us&edition=fundamental","pubTime":"2024-03-13 20:27","pubTimestamp":1710332820,"startTime":"0","endTime":"0","summary":"American depositary receipts of BeiGene jumped after the company said the first doses of its lymphocytic leukemia treatment Brukinsa have been administered to patients in Armenia and Nepal.The stock was up 9% at $179 in premarket trading. Shares had fallen 9% year-to-date when the market closed Tuesday.The oncology company said Wednesday morning that the initial dosing comes as part of a three-year collaboration with a health equity nonprofit, The Max Foundation, and its own nonprofit charitable foundation to provide access to medicine in low- and middle-income countries.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2418816547","title":"BeiGene (NASDAQ:BGNE shareholders incur further losses as stock declines 3.9% this week, taking three-year losses to 51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2418816547","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2418816547?lang=en_us&edition=fundamental","pubTime":"2024-03-10 21:40","pubTimestamp":1710078045,"startTime":"0","endTime":"0","summary":"If you love investing in stocks you're bound to buy some losers. Long term BeiGene, Ltd. ( NASDAQ:BGNE ) shareholders...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bgne/beigene/news/beigene-nasdaqbgne-shareholders-incur-further-losses-as-stoc","is_publish_highlight":false,"gpt_icon":0},{"id":"2417582034","title":"BRIEF-Beigene Files Patent Infringement Suits Against Sandoz And MSN","url":"https://stock-news.laohu8.com/highlight/detail?id=2417582034","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2417582034?lang=en_us&edition=fundamental","pubTime":"2024-03-08 19:12","pubTimestamp":1709896349,"startTime":"0","endTime":"0","summary":"March 8 (Reuters) - Beigene Ltd   :   * BEIGENE:  BEIGENE FILED PATENT INFRINGEMENT SUITS AGAINST SANDOZ AND SEPARATELY AGAINST MSN IN U.S. DISTRICT COURT FOR DISTRICT OF NEW JERSEYSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beigene.com","stockEarnings":[{"period":"1week","weight":0.0195},{"period":"1month","weight":0.2412},{"period":"3month","weight":0.126},{"period":"6month","weight":-0.1139},{"period":"1year","weight":-0.2721},{"period":"ytd","weight":-0.0745}],"compareEarnings":[{"period":"1week","weight":0.0452},{"period":"1month","weight":0.1925},{"period":"3month","weight":0.1858},{"period":"6month","weight":0.1101},{"period":"1year","weight":-0.0094},{"period":"ytd","weight":0.1366}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.03281},{"month":2,"riseRate":0.5,"avgChangeRate":0.020001},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.060772},{"month":4,"riseRate":0.5,"avgChangeRate":0.051983},{"month":5,"riseRate":0.5,"avgChangeRate":-0.030063},{"month":6,"riseRate":0.6,"avgChangeRate":0.018734},{"month":7,"riseRate":0.8,"avgChangeRate":0.062642},{"month":8,"riseRate":0.8,"avgChangeRate":0.040871},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.025087},{"month":10,"riseRate":0.666667,"avgChangeRate":0.006083},{"month":11,"riseRate":0.5,"avgChangeRate":0.130955},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.054912}],"exchange":"SEHK","name":"BEIGENE","nameEN":"BEIGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BEIGENE(06160),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BEIGENE(06160) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BEIGENE,06160,BEIGENE股票,BEIGENE股票老虎,BEIGENE股票老虎国际,BEIGENE行情,BEIGENE股票行情,BEIGENE股价,BEIGENE股市,BEIGENE股票价格,BEIGENE股票交易,BEIGENE股票购买,BEIGENE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BEIGENE(06160),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BEIGENE(06160) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}